BioPharmSignal logoBioPharmSignal

Biotech News

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Context Therapeutics (CNTX)Context TherapeuticsEarnings

Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202 (Nectin-4 x CD3) trial expected in third quarter of 2026 Cash and cash equivalents of $54.5 million

Related news

CNTXContext Therapeutics2026-08-05 20:15 EST

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

View all latest news

Context Therapeutics

Solid-Tumor T-Cell Engagers Context Therapeutics develops bispecific antibodies that bind a tumor antigen and CD3 to recruit T cells against solid tumors. CTIM-76 CTIM-76 targets Claudin 6 and CD3. It is the company's lead Phase 1 program in tumors expressing the developmentally restricted CLDN6 antigen. CT-95 CT-95 is a...

Recent company news

CNTXContext Therapeutics2026-08-05 20:15 EST

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

CNTXContext Therapeutics2026-07-10 20:05 EST

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CNTXContext Therapeutics2026-07-06 20:07 EST

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

CNTXContext Therapeutics2026-06-15 10:30 EST

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

CNTXContext Therapeutics2026-06-09 20:10 EST

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
0.50 USD
Market cap
222.35M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States